Suppr超能文献

高 CD4 细胞计数对接受抗逆转录病毒治疗的 HIV 患者死亡和流失的影响:一项观察性队列研究。

Effects of high CD4 cell counts on death and attrition among HIV patients receiving antiretroviral treatment: an observational cohort study.

机构信息

Guangxi Center for Disease Control and Prevention, Nanning, China.

Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, USA.

出版信息

Sci Rep. 2017 Jun 9;7(1):3129. doi: 10.1038/s41598-017-03384-7.

Abstract

Current WHO guidelines recommend initiating ART regardless of CD4+ cell count. In response, we conducted an observational cohort study to assess the effects of pre-ART CD4+ cell count levels on death, attrition, and death or attrition in HIV treated patients. This large HIV treatment cohort study (n = 49,155) from 2010 to 2015 was conducted in Guangxi, China. We used a Cox regression model to analyze associations between pre-ART CD4+ cell counts and death, attrition, and death or attrition. The average mortality and ART attrition rates among all treated patients were 2.63 deaths and 5.32 attritions per 100 person-years, respectively. Compared to HIV patients with <350 CD4+ cells/mm at ART initiation, HIV patients with >500 CD4+ cells/mm at ART initiation had a significantly lower mortality rate (Adjusted hazard ratio: 0.56, 95% CI: 0.40-0.79), but significantly higher ART attrition rate (AHR: 1.17, 95% CI: 1.03-1.33). Results from this study suggest that HIV patients with high CD4+ cell counts at the time of ART initiation may be at greater risk of treatment attrition. To further reduce ART attrition, it is imperative that patient education and healthcare provider training on ART adherence be enhanced and account for CD4 levels at ART initiation.

摘要

目前,世界卫生组织的指南建议无论 CD4+ 细胞计数如何,都应开始接受抗逆转录病毒治疗。针对这一建议,我们进行了一项观察性队列研究,以评估开始抗逆转录病毒治疗前 CD4+ 细胞计数水平对接受 HIV 治疗患者的死亡、退出治疗和死亡或退出治疗的影响。这项于 2010 年至 2015 年在中国广西进行的大型 HIV 治疗队列研究(n=49155)纳入了所有接受治疗的患者。我们使用 Cox 回归模型分析了开始抗逆转录病毒治疗前 CD4+ 细胞计数与死亡、退出治疗以及死亡或退出治疗之间的关联。所有接受治疗的患者的平均死亡率和抗逆转录病毒治疗退出率分别为每 100 人年 2.63 例死亡和 5.32 例退出治疗。与开始抗逆转录病毒治疗时 CD4+ 细胞<350 个/mm3的 HIV 患者相比,开始抗逆转录病毒治疗时 CD4+ 细胞>500 个/mm3的 HIV 患者的死亡率显著降低(调整后的危险比:0.56,95%可信区间:0.40-0.79),但抗逆转录病毒治疗退出率显著升高(调整后的危险比:1.17,95%可信区间:1.03-1.33)。这项研究的结果表明,开始抗逆转录病毒治疗时 CD4+ 细胞计数较高的 HIV 患者可能面临更高的治疗退出风险。为了进一步降低抗逆转录病毒治疗退出率,必须加强对患者进行抗逆转录病毒治疗依从性的教育,并在开始抗逆转录病毒治疗时考虑 CD4 水平。

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验